These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34975202)

  • 1. WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
    Gamulin M; Bebek M; Gnjidic M
    Acta Clin Croat; 2019 Nov; 58(Suppl 2):73-75. PubMed ID: 34975202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Morris MJ; Rumble RB; Basch E; Hotte SJ; Loblaw A; Rathkopf D; Celano P; Bangs R; Milowsky MI
    J Clin Oncol; 2018 May; 36(15):1521-1539. PubMed ID: 29608397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
    Ferro M; Lucarelli G; Crocetto F; Dolce P; Verde A; La Civita E; Zappavigna S; de Cobelli O; Di Lorenzo G; Facchini BA; Scafuri L; Onofrio L; Porreca A; Busetto GM; Sonpavde G; Caraglia M; Klain M; Terracciano D; De Placido S; Buonerba C
    Crit Rev Oncol Hematol; 2021 Jan; 157():103198. PubMed ID: 33316417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P; Manka L
    Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
    Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
    Omrčen T
    Acta Clin Croat; 2019 Nov; 58(Suppl 2):69-72. PubMed ID: 34975201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.
    Shenoy N; Kohli M
    Indian J Urol; 2016; 32(4):257-261. PubMed ID: 27843206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
    Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach.
    Harada K; Shiota M; Minato A; Matsumoto M; Tomisaki I; Fujisawa M; Fujimoto N
    Onco Targets Ther; 2021; 14():2967-2974. PubMed ID: 33981146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone naïve metastatic prostate cancer: How to treat it?
    Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
    Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
    Adashek JJ; Reed JP; Tandon A; Freedland SJ; Posadas E; Bhowmick N; Chung LW; Freeman M; Figlin RA; Gong J
    Clin Genitourin Cancer; 2020 Dec; 18(6):425-428. PubMed ID: 32631766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
    Xu L; Pachynski RK
    Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care.
    Mittal A; Sridhar SS; Ong M; Jiang DM
    Curr Oncol; 2023 Apr; 30(4):4365-4378. PubMed ID: 37185445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.